

Prostate cancer incidence in hypogonadal men on long-term treatment with testosterone undecanoate injections

A Yassin, A Haider, M Zitzmann, F Saad, A Traish

Institute of Urology and Andrology, Segeberger Kliniken, Norderstedt, Germany
Dresden International University, Dresden, Germany
Private Urology Practice, Bremerhaven, Germany
Centre of Reproductive Medicine, Andrology and Clinical Andrology of the University, Muenster, Germany
Global Medical Affairs Andrology, Bayer Pharma, Berlin, Germany
Gulf Medical University, Ajman, UAE
Dpt of Biochemistry and Dpt of Urology, Boston University School of Medicine, Boston, MA, USA

Introduction: Concerns regarding the safety of testosterone treatment, particularly regarding prostate cancer in elderly men, still hamper the use of testosterone in hypogonadal men.

Methods: Registry studies of 942 men with testosterone levels ≤ 12.1 nmol/L from three German centers. Patients received testosterone undecanoate for up to 16 years.

Results:

In cohort A (mean age: 57.70 ± 6.76 years; Haider), PSA increased from 1.77 ± 0.97 to 2.0 ± 1.01 ng/ml ($p=0.0021$). Prostate volume increased from 28.34 ± 10.79 to 30.72 ± 14.28 ml ($p<0.0001$). 5/300 patients were diagnosed with prostate cancer. The proportion was 1.7% with an incidence of 39.4 per 10,000 patient-years.

In cohort B (mean age: 59.53 ± 8.35 years; Yassin), PSA increased from 0.86 ± 0.57 to 1.38 ± 0.49 ng/ml ($p<0.0001$). Prostate volume increased from 27.9 ± 8.15 to 36.98 ± 7.22 ml ($p<0.0001$). 6/261 patients were diagnosed with prostate cancer. The proportion was 2.3% with an incidence of 54.5 per 10,000 patient-years.

One patient in cohort B was treated with external beam radiation, all other patients underwent radical prostatectomy.

In cohort C (mean age: 42.6 ± 13.4 years; Zitzmann), PSA increased from 1.6 ± 0.4 to 1.9 ± 0.4 ($p<0.001$). Prostate volume increased from 16.9 ± 5.1 to 19.9 ± 5.3 ml ($p<0.001$). No patient was diagnosed with prostate cancer.

Conclusions: The PLCO trial reported an incidence of 116 per 10,000 patient-years (Andriole, NEJM 360(13):1310-9), the ERSPC trial 96.6 (Schröder, NEJM

366(11):981-90). In our registry studies, the incidence of prostate cancer does not suggest an increased risk in hypogonadal men on long-term testosterone treatment.